Hosta plantaginea flower active part as well as preparation method and application thereof

Abstract

The invention relates to the technical field of biological medicines, and particularly discloses an active site of flower of hosta plantaginea, the active site of flower of hosta plantaginea contains kaempferol 3-O-(2G-glucosylrustine-7-O-glucoside, kaempferol 3-O-rustine-7-O-glucoside, kaempferol 3-O-rustine-7-O-glucoside, kaempferol 3-O-glucoside and kaempferol 3-O-glucoside, the active site of flower of hosta plantaginea has an excellent effect of treating prostatitis, and the active site of flower of hosta plantaginea has an excellent effect of treating prostatitis. Meanwhile, the effect of treating benign prostatic hyperplasia is also achieved. Therefore, the active part of the hosta plantaginea flower, as an effective component, has an important application value in preparing the medicine for treating the prostatitis and the benign prostatic hyperplasia.

Description

Technical Field

[0001] The invention relates to the technical field of biomedicine, and in particular to an active part of hosta flower and a preparation method and application thereof. Background Art

[0002] Hosta flower is the flower of Hosta plantaginea (Lam.) Aschers. of the Liliaceae family. It has the effects of clearing away heat and detoxifying, promoting diuresis, and regulating menstruation. It is often used for sore throat, sores, swollen and painful carbuncle, dysuria, and amenorrhea. The research group of the present invention disclosed the use of Hosta flower and its extract in the preparation of drugs for the treatment of chronic prostatitis in the previous invention patent 201710954397.1. Studies have shown that Hosta flower and its extracts and active ingredients have clear and controllable efficacy in the treatment of chronic prostatitis.

[0003] However, it requires a dosage of 1.0 g / kg to 5.0 g / kg to achieve a good effect, and the effect is not obvious at a lower dosage, and its effect in treating prostatitis needs to be further improved. In addition, there is no report on the treatment of prostatic hyperplasia (BPH) by Hosta flos in the prior art. Summary of the invention

[0004] In order to overcome at least one of the technical problems existing in the prior art, the present invention provides a

[0005] The present invention provides an active part of lily of the valley, wherein the active part of lily of the valley contains kaempferol3-O-(2 G -glucosylrutinoside)-7-O-glucoside, kaempferol-3-O-sophoroside-7-O-glucopyranoside, kaempferol-3-O-rutinoside-7-O-glucopyranoside, kaempferol-3-O-sophoroside, and kaempferol-3-O-rutinoside.

[0006] Preferably, the kaempferol 3-O-(2 G-glucosylrutinoside)-7-O-glucoside, kaempferol-3-O-sophoroside-7-O-glucopyranoside, kaempferol-3-O-rutinoside-7-O-glucopyranoside, kaempferol-3-O-sophoroside and kaempferol-3-O-rutinoside contents are respectively:

[0007] kaempferol 3-O-(2 G -glucosylrutinoside)-7-O-glucoside 20~40mg / g;

[0008] kaempferol-3-O-sophoroside-7-O-glucopyranoside 20~30mg / g;

[0009] kaempferol-3-O-rutinoside-7-O-glucopyranoside 40~60mg / g;

[0010] kaempferol-3-O-sophoroside 50~70mg / g;

[0011] kaempferol-3-O-rutinoside 20~40mg / g.

[0012] More preferably, the kaempferol 3-O-(2 G -glucosylrutinoside)-7-O-glucoside, kaempferol-3-O-sophoroside-7-O-glucopyranoside, kaempferol-3-O-rutinoside-7-O-glucopyranoside, kaempferol-3-O-sophoroside and kaempferol-3-O-rutinoside contents are respectively:

[0013] kaempferol 3-O-(2 G -glucosylrutinoside)-7-O-glucoside 30~35mg / g;

[0014] kaempferol-3-O-sophoroside-7-O-glucopyranoside 25~30mg / g;

[0015] kaempferol-3-O-rutinoside-7-O-glucopyranoside 40~45mg / g;

[0016] kaempferol-3-O-sophoroside 55~70mg / g;

[0017] kaempferol-3-O-rutinoside 30~35mg / g.

[0018] The inventors have found in their research that the kaempferol 3-O-(2 G The active parts of Hosta flower are kaempferol-3-O-sophoroside-7-O-glucopyranoside, kaempferol-3-O-rutinoside-7-O-glucopyranoside, kaempferol-3-O-sophoroside and kaempferol-3-O-rutinoside, which have excellent effects on treating prostatitis and prostatic hyperplasia.

[0019] The present invention also provides a method for preparing the active fraction of Hosta odorata, which comprises the following steps:

[0020] (1) extracting hosta flowers with an organic solvent to obtain an organic solvent extract; concentrating and drying the organic solvent extract to obtain an organic solvent extract of hosta flowers;

[0021] (2) The organic solvent extract of Hosta odorata is loaded onto a macroporous resin column, and first eluted with an ethanol aqueous solution with a volume fraction of 8 to 12%, and the eluate eluted with the ethanol aqueous solution with a volume fraction of 8 to 12% is discarded; then eluted with an ethanol aqueous solution with a volume fraction of 26 to 30%, and the eluate eluted with the ethanol aqueous solution with a volume fraction of 26 to 30% is collected, and the active fraction of Hosta odorata is obtained after concentrating and drying.

[0022] Preferably, in step (2), the amount of ethanol aqueous solution with a volume fraction of 8 to 12% is 3 to 6 times the column volume; the amount of ethanol aqueous solution with a volume fraction of 26 to 30% is 3 to 6 times the column volume.

[0023] Most preferably, in step (2), first elute with 5 times the column volume of a 10% ethanol-water solution, discard the eluate eluted with the 10% ethanol-water solution; then elute with 5 times the column volume of a 28% ethanol-water solution, collect the eluate eluted with the 28% ethanol-water solution, and concentrate and dry to obtain the active fraction of the hosta flower.

[0024] The inventors surprisingly found in the research that the macroporous resin elution conditions of the present invention are very critical. Only the active part of the hosta prepared under the macroporous resin elution conditions described in the present invention can be enriched to obtain a large amount of effective ingredients for treating prostatitis and prostatic hyperplasia, and compared with the organic solvent extract of the hosta, its effect on treating prostatitis and prostatic hyperplasia can be greatly improved; while the active part of the hosta prepared under other macroporous resin elution conditions cannot be enriched to obtain a large amount of effective ingredients for treating prostatitis and prostatic hyperplasia, and compared with the organic solvent extract of the hosta, its effect on treating prostatitis and prostatic hyperplasia cannot be improved or greatly improved.

[0025] Preferably, the organic solvent in step (1) is ethanol.

[0026] Preferably, the ethanol refers to an ethanol aqueous solution with a volume fraction of 50 to 95%.

[0027] Preferably, the extraction method is percolation.

[0028] Preferably, the percolation method is specifically as follows: taking Hosta flowers, placing them in a percolation barrel, and then performing percolation extraction with ethanol to obtain an organic solvent extract after the extraction is completed; and concentrating and drying the organic solvent extract to obtain the Hosta flower organic solvent extract, i.e., the Hosta flower extract.

[0029] Further preferably, percolation extraction is first carried out with an ethanol-water solution with a volume fraction of 90-95% to obtain an ethanol extract with a volume fraction of 90-95%; then percolation extraction is carried out with an ethanol-water solution with a volume fraction of 60-75% to obtain an ethanol extract with a volume fraction of 60-75%; the ethanol extract with a volume fraction of 90-95% and the ethanol extract with a volume fraction of 60-75% are combined to obtain an organic solvent extract; the organic solvent extract is concentrated and dried to obtain the hosta organic solvent extract, i.e., the hosta extract.

[0030] Most preferably, percolation extraction is first performed with a 95% by volume ethanol-water solution to obtain a 95% by volume ethanol extract; then percolation extraction is performed with a 70% by volume ethanol-water solution to obtain a 70% by volume ethanol extract; the 95% by volume ethanol extract and the 70% by volume ethanol extract are combined to obtain a hosta organic solvent extract; the organic solvent extract is concentrated and dried to obtain a hosta organic solvent extract, i.e., the hosta extract.

[0031] Preferably, the hosta flower is a dried hosta flower.

[0032] Further preferably, the ratio of the volume fraction of 90-95% ethanol aqueous solution to the volume fraction of Hosta is 1kg:15-25L; the ratio of the volume fraction of 60-75% ethanol aqueous solution to the volume fraction of Hosta is 1kg:15-25L.

[0033] Most preferably, the ratio of the volume fraction of 90-95% ethanol aqueous solution to the volume fraction of Hosta is 1kg:20L; the ratio of the volume fraction of 60-75% ethanol aqueous solution to the volume fraction of Hosta is 1kg:20L.

[0034] More preferably, the percolation rate of the percolation extraction is 3 to 5 ml / (kg·min).

[0035] More preferably, the percolation temperature of the percolation extraction is 20-30°C.

[0036] The present invention also provides an application of the active part of the hosta flower in preparing a medicine for treating prostatitis.

[0037] The present invention also provides an application of the active part of Hosta odorata in preparing a medicine for treating prostatic hyperplasia.

[0038] Beneficial effects: The present invention provides a new composition of the active part of Hosta flower; studies have shown that it contains kaempferol 3-O-(2 GThe active parts of the hosta flower of the present invention, which are kaempferol-3-O-sophoroside-7-O-glucopyranoside, kaempferol-3-O-rutinoside-7-O-glucopyranoside, kaempferol-3-O-sophoroside and kaempferol-3-O-rutinoside, have excellent effects in treating prostatitis and prostatic hyperplasia. Therefore, the active parts of the hosta flower of the present invention are used as effective ingredients to prepare drugs for treating prostatitis and prostatic hyperplasia, which has important application value. DETAILED DESCRIPTION

[0039] The present invention is further explained below in conjunction with specific examples, but the examples do not limit the present invention in any form.

[0040] Example 1 Preparation of the active fraction of Hosta odorata

[0041] (1) taking dried hosta flowers, placing them in a percolation barrel, first percolating with a 95% by volume ethanol aqueous solution to obtain a 95% by volume ethanol extract; then percolating with a 70% by volume ethanol aqueous solution to obtain a 70% by volume ethanol extract; combining the 95% by volume ethanol extract and the 70% by volume ethanol extract to obtain an organic solvent extract; concentrating and drying the organic solvent extract to obtain a hosta flower organic solvent extract;

[0042] (2) The organic solvent extract of Hosta odorata is loaded onto a D101 macroporous resin column, and first eluted with 5 times the column volume of a 10% ethanol aqueous solution, and the eluate eluted with the 10% ethanol aqueous solution is discarded; then eluted with 5 times the column volume of a 28% ethanol aqueous solution, and the eluate eluted with the 28% ethanol aqueous solution is collected, and the active fraction of Hosta odorata is obtained after concentrating and drying.

[0043] Kaempferol 3-O-(2 G-glucosylrutinoside)-7-O-glucoside, kaempferol-3-O-sophoroside-7-O-glucopyranoside, kaempferol-3-O-rutinoside-7-O-glucopyranoside, kaempferol-3-O-sophoroside and kaempferol-3-O-rutinoside were used as reference substances to establish a standard curve; then the kaempferol 3-O-(2 G -glucosylrutinoside)-7-O-glucoside, kaempferol-3-O-sophoroside-7-O-glucopyranoside, kaempferol-3-O-rutinoside-7-O-glucopyranoside, kaempferol-3-O-sophoroside and kaempferol-3-O-rutinoside content;

[0044] The results showed that among the active parts of the hosta prepared in this example,

[0045] kaempferol 3-O-(2 G -glucosylrutinoside)-7-O-glucoside content is 30mg / g;

[0046] The content of kaempferol-3-O-sophoroside-7-O-glucopyranoside is 27 mg / g;

[0047] The content of kaempferol-3-O-rutinoside-7-O-glucopyranoside is 43 mg / g;

[0048] The content of kaempferol-3-O-sophoroside is 57mg / g;

[0049] The content of kaempferol-3-O-rutinoside is 33 mg / g.

[0050] The HPLC conditions are as follows: the liquid chromatography column is a Shimadzu InerSustain C18 column; the mobile phase is acetonitrile-0.2% phosphoric acid solution (20:80); the detection wavelength is 254 nm; the flow rate is 1.0 mL / min; the column temperature is 30° C.; and the injection volume is 10 μL.

[0051] Comparative Example 1 Preparation of the Active Part of Hosta odorata

[0052] Take dried hosta flowers, place them in a percolation barrel, first perform percolation extraction with an ethanol aqueous solution with a volume fraction of 95% to obtain an ethanol extract with a volume fraction of 95%; then perform percolation extraction with an ethanol aqueous solution with a volume fraction of 70% to obtain an ethanol extract with a volume fraction of 70%; combine the ethanol extract with a volume fraction of 95% and the ethanol extract with a volume fraction of 70% to obtain an organic solvent extract; concentrate and dry the organic solvent extract to obtain a hosta flower organic solvent extract, i.e., the hosta flower extract;

[0053] Among them, the ratio of the volume fraction of 95% ethanol aqueous solution to the amount of hosta is 1kg:20L; the ratio of the volume fraction of 70% ethanol aqueous solution to the amount of hosta is 1kg:20L; the percolation rate of the percolation extraction is 4ml / (kg·min); and the percolation temperature is 25°C.

[0054] Comparative Example 2 Preparation of the Active Part of Hosta Flos

[0055] (1) taking dried hosta flowers, placing them in a percolation barrel, first percolating with a 95% by volume ethanol aqueous solution to obtain a 95% by volume ethanol extract; then percolating with a 70% by volume ethanol aqueous solution to obtain a 70% by volume ethanol extract; combining the 95% by volume ethanol extract and the 70% by volume ethanol extract to obtain an organic solvent extract; concentrating and drying the organic solvent extract to obtain a hosta flower organic solvent extract;

[0056] (2) The organic solvent extract of Hosta odorata is loaded onto a D101 macroporous resin column, and first eluted with 5 times the column volume of a 5% ethanol aqueous solution, and the eluate eluted with the 5% ethanol aqueous solution is discarded; then eluted with 5 times the column volume of a 15% ethanol aqueous solution, and the eluate eluted with the 15% ethanol aqueous solution is collected, and the active fraction of Hosta odorata is obtained after concentrating and drying.

[0057] Comparative Example 3 Preparation of the Active Part of Hosta odorata

[0058] (1) taking dried hosta flowers, placing them in a percolation barrel, first percolating with a 95% by volume ethanol aqueous solution to obtain a 95% by volume ethanol extract; then percolating with a 70% by volume ethanol aqueous solution to obtain a 70% by volume ethanol extract; combining the 95% by volume ethanol extract and the 70% by volume ethanol extract to obtain an organic solvent extract; concentrating and drying the organic solvent extract to obtain a hosta flower organic solvent extract;

[0059] (2) The organic solvent extract of Hosta odorata is loaded onto a D101 macroporous resin column, and first eluted with 5 times the column volume of a 30% ethanol aqueous solution, and the eluate eluted with the 30% ethanol aqueous solution is discarded; then eluted with 5 times the column volume of a 60% ethanol aqueous solution, and the eluate eluted with the 60% ethanol aqueous solution is collected, and the active fraction of Hosta odorata is obtained after concentrating and drying.

[0060] Experimental Example 1 Experiment on the treatment of prostatitis and prostatic hyperplasia with the hosta flower extract of the present invention

[0061] Rat modeling: SPF grade SD male rats were used as experimental subjects, weighing 160-180 grams. After one week of adaptive feeding, 5 mg kg-1 of testosterone propionate (testosterone propionate can be dissolved in olive oil and the dosage concentration is 1 ml / kg) was injected subcutaneously into the abdominal cavity once a day for two consecutive weeks.

[0062] After successful modeling, the model rats were randomly divided into 6 groups, 8 rats / group, and given drugs by gavage every day, and testosterone propionate was injected subcutaneously every 2 days for 42 days. At the same time, 8 normal SD male rats were taken as the normal group, and the rats in the normal group were injected with the same dose of olive oil. The activity, diet and excretion of the rats were observed every day.

[0063] After the intragastric administration, the rats were killed on the 43rd day, the abdomen was opened and the prostate tissue was quickly removed, the wet weight of the prostate tissue was weighed, and the prostate index was calculated. The specific formula was: prostate index = rat prostate tissue wet weight / rat body weight × 1000; and according to the ELISA kit instructions, the levels of IL-1β, IL-6, and TNF-α in the prostate tissue of each group were detected. The results of the prostate index of rats in each group are shown in Table 1; the levels of IL-1β, IL-6, and TNF-α in the prostate tissue of each group are shown in Table 2.

[0064] The intragastric administration conditions of each group are as follows:

[0065] Normal group (Control): equal volume of 0.3% CMC-Na solution

[0066] Model group: equal volume of 0.3% CMC-Na solution

[0067] Experimental group 1: the active fraction of Hosta odorata prepared in Example 1, with an intragastric dose of 200 mg / kg / d;

[0068] Experimental group 2: the active part of Hosta flower prepared in comparative example 1, with an intragastric dose of 200 mg / kg / d;

[0069] Experimental group 3: the active part of Hosta flower prepared in comparative example 2, with an intragastric dose of 200 mg / kg / d;

[0070] Experimental group 4: the active part of Hosta flower prepared in comparative example 3, with an intragastric dose of 200 mg / kg / d;

[0071] Experimental group 5: positive drug Prostat tablets (Nanjing Meirui Pharmaceutical Co., Ltd.), oral gavage dose of 200 mg / kg / d.

[0072] Table 1. Effect of the effective parts of Hosta odorata on rat prostate index

[0073] Group Testing drugs Prostate Index Normal group - 1.07±0.08 Model Group - 2.91±0.36 Experimental Group 1 Example 1: The active fraction of Hosta odorata prepared 1.28±0.21 Experimental Group 2 Comparative Example 1: The active fraction of Hosta flower prepared 2.51±0.27 Experimental Group 3 Comparative Example 2: Active fraction of Hosta flower prepared 2.17±0.25 Experimental Group 4 Comparative Example 3: Active fraction of Hosta flower prepared 2.48±0.33 Experimental Group 5 Positive drug Pushitai tablets 1.53±0.15

[0074] It can be seen from the experimental data in Table 1 that the prostate index of the rats in the model group is significantly higher than that in the normal group, which indicates that the rat model of prostate hyperplasia is successfully established in the present invention.

[0075] It can be seen from the experimental data in Table 1 that the prostate index of the rats in the experimental group 1 (the active fraction of the hosta prepared in Example 1 was administered intragastricly) was significantly lower than that of the rats in the model group and close to that of the normal group; at the same time, its prostate index was also significantly lower than that of the positive drug Pushitai tablets; this shows that the kaempferol 3-O-(2 G -glucosylrutinoside)-7-O-glucoside, kaempferol-3-O-sophoroside-7-O-glucopyranoside, kaempferol-3-O-rutinoside-7-O-glucopyranoside, kaempferol-3-O-sophoroside and kaempferol-3-O-rutinoside, which have excellent therapeutic effects on prostate hyperplasia; and their therapeutic effects on prostate hyperplasia are better than those of the positive drug Pushitai tablets.

[0076] It can be seen from the experimental data in Table 1 that the prostate index of the rats in Experimental Group 1 (the active part of the Hosta prepared by oral gavage in Example 1) is also significantly lower than that of the rats in Experimental Group 2 (the active part of the Hosta prepared by oral gavage in Comparative Example 1). This indicates that the effective part of the Hosta prepared by further subjecting the organic solvent extract of the Hosta to the elution conditions of the macroporous resin of the present invention has a further significantly improved effect on treating prostate hyperplasia compared with the organic solvent extract of the Hosta; thus, the prepared effective part of the Hosta has a very excellent effect on treating prostate hyperplasia.

[0077] It can be seen from the experimental data in Table 1 that the prostate index of the rats in experimental groups 3 and 4 (the active part of the hosta prepared by oral gavage in comparative examples 2 and 3) was not significantly reduced compared with that of the rats in experimental group 2; the reduction was much smaller than the prostate index of the rats in experimental group 1 (the active part of the hosta prepared by oral gavage in example 1); this shows that the elution conditions of the macroporous resin column of the present invention are very critical. Only when the organic solvent extract of the hosta is further eluted under the macroporous resin column elution conditions of the present invention to obtain the effective part of the hosta, its effect in treating prostate hyperplasia can be further significantly improved compared with the organic solvent extract of the hosta; while the effective part of the hosta prepared under other macroporous resin column elution conditions cannot be further significantly improved compared with the organic solvent extract of the hosta.

[0078] Table 2. Effects of the effective fraction of Hosta odorata on inflammatory factors in rat prostate tissue

[0079]

[0080] It can be seen from the experimental data in Table 1 that the content of inflammatory factors (IL-1β, IL-6, TNF-α) in the prostate of the rats in the experimental group 2 (the active part of the lily of the valley prepared by oral gavage in comparative example 1) is lower than that in the model group, but the reduction is not large; this shows that: the organic solvent extract of the lily of the valley obtained by extracting the lily of the valley with an organic solvent has a certain anti-prostatitis effect, but it is not significant. However, the content of inflammatory factors (IL-1β, IL-6, TNF-α) in the prostate of the rats in the experimental group 1 (the active part of the lily of the valley prepared by oral gavage in comparative example 1) is greatly reduced compared with the model group, and is also greatly reduced compared with the rats in the experimental group 2 (the active part of the lily of the valley prepared by oral gavage in comparative example 1); this shows that: the kaempferol 3-O-(2 G -glucosylrutinoside)-7-O-glucoside, kaempferol-3-O-sophoroside-7-O-glucopyranoside, kaempferol-3-O-rutinoside-7-O-glucopyranoside, kaempferol-3-O-sophoroside and kaempferol-3-O-rutinoside, the anti-prostatitis effect of the active parts of the hosta flower has been further greatly improved compared with the organic solvent extract of the hosta flower; the anti-prostatitis effect is equivalent to that of the positive drug Pushitai tablets, so that the prepared effective parts of the hosta flower have a very excellent effect on treating prostatic hyperplasia.

[0081] It can be seen from the experimental data in Table 1 that the inflammatory factors in the prostate of the rats in experimental groups 3 and 4 (the active fraction of the Hosta prepared by gavage comparison examples 2 and 3) were not significantly reduced compared with those in the rats in experimental group 2 (the active fraction of the Hosta prepared by gavage comparison example 1); the reduction was much smaller than that in the rats in experimental group 1 (the active fraction of the Hosta prepared by gavage example 1); this shows that the elution conditions of the macroporous resin column of the present invention are very critical. Only when the organic solvent extract of the Hosta is further subjected to the elution conditions of the macroporous resin column of the present invention to obtain the effective fraction of the Hosta, its anti-prostatitis effect can be further significantly improved compared with the organic solvent extract of the Hosta; and the effective fraction of the Hosta prepared by other macroporous resin column elution conditions cannot be further significantly improved compared with the organic solvent extract of the Hosta.

Claims

1. An active part of Hosta odorata, characterized in that: The active part of the hosta flower contains kaempferol 3-O-(2 G -glucosylrutinoside)-7-O-glucoside, kaempferol-3-O-sophoroside-7-O-glucopyranoside, kaempferol-3-O-rutinoside-7-O-glucopyranoside, kaempferol-3-O-sophoroside, and kaempferol-3-O-rutinoside.

2. The active fraction of Hosta odorata according to claim 1, characterized in that The kaempferol 3-O-(2 G -glucosylrutinoside)-7-O-glucoside, kaempferol-3-O-sophoroside-7-O-glucopyranoside, kaempferol-3-O-rutinoside-7-O-glucopyranoside, kaempferol-3-O-sophoroside and kaempferol-3-O-rutinoside contents are respectively: kaempferol 3-O-(2 G -glucosylrutinoside)-7-O-glucoside 20~40mg / g; kaempferol-3-O-sophoroside-7-O-glucopyranoside 20~30mg / g; kaempferol-3-O-rutinoside-7-O-glucopyranoside 40~60mg / g; kaempferol-3-O-sophoroside 50~70mg / g; kaempferol-3-O-rutinoside 20~40mg / g.

3. The active fraction of Hosta odorata according to claim 2, characterized in that: The kaempferol 3-O-(2 G -glucosylrutinoside)-7-O-glucoside, kaempferol-3-O-sophoroside-7-O-glucopyranoside, kaempferol-3-O-rutinoside-7-O-glucopyranoside, kaempferol-3-O-sophoroside and kaempferol-3-O-rutinoside contents are respectively: kaempferol 3-O-(2 G -glucosylrutinoside)-7-O-glucoside 30~35mg / g; kaempferol-3-O-sophoroside-7-O-glucopyranoside 25~30mg / g; kaempferol-3-O-rutinoside-7-O-glucopyranoside 40~45mg / g; kaempferol-3-O-sophoroside 55~70mg / g; kaempferol-3-O-rutinoside 30~35mg / g.

4. The method for preparing the active fraction of Hosta odorata according to any one of claims 1 to 3, characterized in that: The following steps are included: (1) extracting hosta flowers with an organic solvent to obtain an organic solvent extract; concentrating and drying the organic solvent extract to obtain an organic solvent extract of hosta flowers; (2) The organic solvent extract of Hosta odorata is loaded onto a macroporous resin column, and first eluted with an ethanol aqueous solution with a volume fraction of 8 to 12%, and the eluate eluted with the ethanol aqueous solution with a volume fraction of 8 to 12% is discarded; then eluted with an ethanol aqueous solution with a volume fraction of 26 to 30%, and the eluate eluted with the ethanol aqueous solution with a volume fraction of 26 to 30% is collected, and the active fraction of Hosta odorata is obtained after concentrating and drying.

5. The preparation method according to claim 4, characterized in that: In step (2), the amount of the ethanol aqueous solution with a volume fraction of 8 to 12% is 3 to 6 times the column volume; the amount of the ethanol aqueous solution with a volume fraction of 26 to 30% is 3 to 6 times the column volume.

6. The preparation method according to claim 5, characterized in that: In step (2), firstly, elution is performed with 5 times the column volume of 10% ethanol aqueous solution, and the eluate eluted with the 10% ethanol aqueous solution is discarded; then, elution is performed with 5 times the column volume of 28% ethanol aqueous solution, and the eluate eluted with the 28% ethanol aqueous solution is collected, and the active fraction of the hosta flower is obtained after concentration and drying.

7. The preparation method according to claim 4, characterized in that: The organic solvent described in step (1) is ethanol.

8. The preparation method according to claim 7, characterized in that: The ethanol mentioned above refers to an ethanol aqueous solution with a volume fraction of 50 to 95%.

9. Use of the active fraction of Hosta odorifera according to any one of claims 1 to 3 in the preparation of a medicament for treating prostatitis.

10. Use of the active fraction of Hosta odorifera according to any one of claims 1 to 3 in the preparation of a medicament for treating prostatic hyperplasia.

Images